Biogen’s Reversal Could Change the Course of Alzheimer’s
CMC on the Verge of Alzheimer’s Game-Changer Failed Alzheimer’s study could have led to disease modifying medication Pharmaceutical company, Biogen, recently revealed a plan to resurrect its experimental Alzheimer’s drug, aducanumab, months after the study’s failure and abrupt closure. Biogen began using aducanumab in 2017 to remove sticky proteins in the brain, called beta amyloid, that are linked to Alzheimer’s disease. Aducanumab (BIIB037) is a human monoclonal antibody studied for the treatment of early Alzheimer’s. Columbus Memory Center was one of the first in the world to [...]